Simone Da Cruz, Kylie Mason, William Renwick, Joanne M Said, Briony A Cutts
{"title":"妊娠期毛细胞白血病的处理。","authors":"Simone Da Cruz, Kylie Mason, William Renwick, Joanne M Said, Briony A Cutts","doi":"10.1177/1753495X251356377","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hairy cell leukaemia (HCL) represents less 1% of all lymphoid neoplasms with cases rarely reported in pregnancy. Management of HCL requires multidisciplinary care to optimise maternal and neonatal outcomes.</p><p><strong>Methods: </strong>A literature search of Ovid MEDLINE and EMBASE for 'hairy cell leukaemia' and 'Pregnancy' was undertaken.</p><p><strong>Results: </strong>Thirteen cases were reviewed including three within our own institutions. Interferon-alpha was the most prominent treatment at varying doses in n = 3 (23%) patients. Other management included antenatal cladribine and rituximab, post-partum cladribine with and without rituximab, laparoscopic splenectomy and termination of pregnancy. 46.1% (n = 6) of patients birthed vaginally. Due to thrombocytopenia, there was a greater proportion of caesarean delivery under general anaesthetic and half of the cases documented bleeding complications.</p><p><strong>Conclusion: </strong>Diagnosis and management of HCL in pregnancy is difficult. Women can be managed safely and outcome aims should be the same as non-pregnant patients.</p>","PeriodicalId":51717,"journal":{"name":"Obstetric Medicine","volume":" ","pages":"1753495X251356377"},"PeriodicalIF":0.5000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367712/pdf/","citationCount":"0","resultStr":"{\"title\":\"Management of hairy cell leukaemia in pregnancy.\",\"authors\":\"Simone Da Cruz, Kylie Mason, William Renwick, Joanne M Said, Briony A Cutts\",\"doi\":\"10.1177/1753495X251356377\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hairy cell leukaemia (HCL) represents less 1% of all lymphoid neoplasms with cases rarely reported in pregnancy. Management of HCL requires multidisciplinary care to optimise maternal and neonatal outcomes.</p><p><strong>Methods: </strong>A literature search of Ovid MEDLINE and EMBASE for 'hairy cell leukaemia' and 'Pregnancy' was undertaken.</p><p><strong>Results: </strong>Thirteen cases were reviewed including three within our own institutions. Interferon-alpha was the most prominent treatment at varying doses in n = 3 (23%) patients. Other management included antenatal cladribine and rituximab, post-partum cladribine with and without rituximab, laparoscopic splenectomy and termination of pregnancy. 46.1% (n = 6) of patients birthed vaginally. Due to thrombocytopenia, there was a greater proportion of caesarean delivery under general anaesthetic and half of the cases documented bleeding complications.</p><p><strong>Conclusion: </strong>Diagnosis and management of HCL in pregnancy is difficult. Women can be managed safely and outcome aims should be the same as non-pregnant patients.</p>\",\"PeriodicalId\":51717,\"journal\":{\"name\":\"Obstetric Medicine\",\"volume\":\" \",\"pages\":\"1753495X251356377\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367712/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetric Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/1753495X251356377\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetric Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1753495X251356377","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Background: Hairy cell leukaemia (HCL) represents less 1% of all lymphoid neoplasms with cases rarely reported in pregnancy. Management of HCL requires multidisciplinary care to optimise maternal and neonatal outcomes.
Methods: A literature search of Ovid MEDLINE and EMBASE for 'hairy cell leukaemia' and 'Pregnancy' was undertaken.
Results: Thirteen cases were reviewed including three within our own institutions. Interferon-alpha was the most prominent treatment at varying doses in n = 3 (23%) patients. Other management included antenatal cladribine and rituximab, post-partum cladribine with and without rituximab, laparoscopic splenectomy and termination of pregnancy. 46.1% (n = 6) of patients birthed vaginally. Due to thrombocytopenia, there was a greater proportion of caesarean delivery under general anaesthetic and half of the cases documented bleeding complications.
Conclusion: Diagnosis and management of HCL in pregnancy is difficult. Women can be managed safely and outcome aims should be the same as non-pregnant patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
